Invitation to Roche ’s virtual Neuroscience Update IR Event

   We are pleased to invite investors and analysts to participate in our virtual event onMonday,  30 October2023, highlighting Roche ’s Neuroscience portfolio, including the latest data presented at ECTRIMS 2023 (Ocrevus, fenebrutinib) and CTAD 2023 (trontinemab, gamma-secretase modulator). 17:00 – 18:15 CET / 16:00 - 17:15GMT12:00 – 1:15pmEDT / 9:00 – 10:15 am PDT  The webinar will start with presentations, followed by a Q&A session (live access to the speakers). The slides will be available for downloadat 16:00 CET on the day of the event.>click here Access to virtual event (pre-registration required)Please pre-register for our webinarhere*.  Should you be unable to register for the webinar due to your company IT policy, please send an e-mail [e-mail].  A replay of the webcast will be available via>ir.roche.com *privacy notice  Best regards,  Bruno EschliHead of Investor Relations    Roche Investor Relations Dr. Bruno EschliPhone: [phone]e-mail:[e-mail] Dr. SabineBorngr äberPhone: [phone]e-mail:[e-mail] Dr. BirgitMasjostPhone: [phone]e-mail:[e-mail] Dr. Gerard TobinPhone: [phone]e-mail:[e-mail]   Investor Relations North America Loren KalmPhone: [phone]e-mail:[e-mail]  

Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news